Darin Olson
Endocrinology, Diabetes & Metabolism · Fort Collins, CONPI 1043324700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Lilly USA, LLC at 25.2% of the total. 2024 is the largest year on record at $410, more than ten times the $25 reported in 2021. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CO, where the typical reported total is $963.
Across 39 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$243
- Medtronic$208
- Tandem Diabetes Care, Inc.$89
- Dexcom, Inc.$73
- BETA Bionics, Inc.$57
- Abbott$43
- plus $251 from 11 others
Across 53 payments — averaging $2847.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$97K
- Kowa Research Institute, Inc.$54K
What the payments were for
- Food & beverage$963100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $243 |
| Medtronic | 1 | $208 |
| Tandem Diabetes Care, Inc. | 4 | $89 |
| Dexcom, Inc. | 4 | $73 |
| BETA Bionics, Inc. | 2 | $57 |
| Abbott | 2 | $43 |
| Rhythm Pharmaceuticals, Inc. | 2 | $43 |
| Novo Nordisk | 2 | $35 |
| Insulet Corporation | 2 | $29 |
| Radius Health, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Bayer | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Amgen | 1 | $18 |
| AbbVie | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$208
How this compares
$963 in reported general payments places this provider in the 50th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 34 | $92,428 |
| OzempicSemaglutide | 58 | $77,199 |
| ForteoTeriparatide | 15 | $61,197 |
| TrulicityDulaglutide | 45 | $56,906 |
| JardianceEmpagliflozin | 25 | $25,129 |
| JanuviaSitagliptin Phosphate | 17 | $15,717 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,455 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 35 | $10,765 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $10,696 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $6,056 |
| Testosterone | 22 | $4,563 |
| Hydrocortisone | 26 | $2,034 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $1,940 |
| Alendronate Sodium | 172 | $1,930 |
| Levothyroxine Sodium | 168 | $1,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Trulicity | $243 | $118,10260 claims |
| Radius Health, Inc.Tymlos | $20 | $92,42834 claims |
| Novo NordiskOzempic | $35 | $77,19958 claims |
| AbbVieSynthroid | $15 | $77312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Fort Collins
- Polina KaloyanovaFort Collins$2K
- Alejandro MunozFort Collins$2K
- Barbara WidomFort Collins$2K
- Meriam IzonFort Collins$1K
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.